SillaJen's BAL0891 confirms anticancer effect at European Society for Medical Oncology; response rate of 21.4% in combination group
Predicted impact: Low
Conference data on BAL0891 repeats trial results already reported in the last 14 days.
SillaJen신라젠
215600 · KOSDAQ · ₩215600 · 신라젠
₩2,130▼ ₩10 (0.47%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y −30.05%
- Market cap
- ₩295B
- Enterprise value
- ₩289B
- P/E
- —
- P/B
- 2.9×
- Dividend yield
- 0.0%
- ROE
- −24.0%
- Net margin
- −224.4%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−60.6% from the high
₩1,780Today: ₩2,120 – ₩2,180₩5,400
Returns
- 1W−4.1%
- 1M−4.9%
- 3M+10.1%
- 6M−40.6%
- YTD−39.2%
- 1Y−30.0%
- Volume today
- 553,584
- 1.0× the 20-day average
- Traded today
- ₩1.2B
- Listed shares
- 138,553,564
- EPS (12 months)
- −₩174
- Earnings yield −8.2%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 42 of 100 (50 is a normal day for this stock).
- SentimentPositiveNews: Headlines report positive trial results and signs of efficacy at a major conference. Community: 0 bullish, 0 bearish posts this week.
- MomentumFlat-4.7% over the last month; the price is below its 20-day average.
- News impactSome5 news items and filings in two weeks; 0 rated high impact, 2 medium.
Signals describe activity, not recommendations. Not financial advice.
SillaJen stock overview
SillaJen (신라젠, KRX: 215600) is listed on KOSDAQ, in the Biotech & Pharma sector. This Korean biotech company was founded in 2006 to develop cancer drugs. Its shares closed at ₩2,130 on Oct 27, 2026, down 0.47% on the day, giving it a market value of ₩295B.
Key facts
- Market cap
- ₩295B
- Sector
- Biotech & Pharma
- Latest price change
- −0.47%
- As of
- Oct 27, 2026
- Main business
- This Korean biotech company was founded in 2006 to develop cancer drugs.
Quick answers about SillaJen
- What does SillaJen do?
- This Korean biotech company was founded in 2006 to develop cancer drugs. Its pipeline includes oncolytic viruses that selectively infect and destroy cancer cells while stimulating the immune system, including combination therapies with immune checkpoint inhibitors, and mitotic checkpoint inhibitors targeting TTK and PLK1 kinases. It also has a pharmaceutical segment developing generic and improved injectable and prescription drugs, five of which are approved and sold in the domestic market, and its revenue comes from co-development, licensing, and drug sales.
- What is the market cap of SillaJen?
- The market capitalisation of SillaJen was ₩295B at the close on Oct 27, 2026.
- Who are the largest shareholders of SillaJen?
- According to the latest official filings, the largest reported holders are Jo Hwan-u (0.55%, as of Jul 2, 2025); THE EMERGING MARKETS SMALL CAP SERIES (0.10%, as of Jul 31, 2026); National Pension Service (0.09%, as of Dec 31, 2023).
- When is the next earnings report from SillaJen?
- Korean companies rarely announce results dates in advance. Based on when SillaJen filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own SillaJen?
- Yes. The National Pension Service held 0.09% of SillaJen shares as of Dec 31, 2023.
Company profile
This Korean biotech company was founded in 2006 to develop cancer drugs. Its pipeline includes oncolytic viruses that selectively infect and destroy cancer cells while stimulating the immune system, including combination therapies with immune checkpoint inhibitors, and mitotic checkpoint inhibitors targeting TTK and PLK1 kinases. It also has a pharmaceutical segment developing generic and improved injectable and prescription drugs, five of which are approved and sold in the domestic market, and its revenue comes from co-development, licensing, and drug sales.
Written by AI from the company's latest annual report.
- Korean name
- 신라젠
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 박상근, 한상규
- Founded
- Mar 2006
- Listed
- Dec 2016
- Listed shares
- 138,553,564
- Fiscal year ends
- Month 12
- Website
- www.sillajen.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent news
[BioS] SillaJen Presents Interim Results of Phase 1 Solid Tumor Trial of TTK/PLK1 at ESMO
Predicted impact: Low
Interim early-stage trial data presented at a conference; preclinical-stage news is vague.
SillaJen unveils interim results of BAL0891 anticancer drug trial at European Society for Medical Oncology
Predicted impact: Low
Recent filings
See all- Major management matter relevant to investorsSep 15, 2026
- [Amended] Notice of Stock Purchase Option GrantSep 3, 2026
- [Amended] Notice of Stock Purchase Option GrantSep 3, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Amended: Quarterly report (Mar 2026)Aug 14, 2026
Titles in Korean until English translations are added.
Also known as: SillaJen / 신라젠 / 215600 / KRX:215600
Source: KRX statistical information